Exhibit
10.1


 


SECURITIES
PURCHASE AGREEMENT


 


This
SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 8, 2021 by and among Advaxis,
Inc., a Delaware corporation (the “Company”), and the Investors identified on the Schedule of Investors attached hereto
as Exhibit A (each an “Investor” and collectively the “Investors”).


 


Recitals



 


A.
The Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”) and/or Rule 506 of Regulation
D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”)
under the 1933 Act; and;


 


B.
The Investors wish to purchase from the Company, and the Company wishes to sell and issue to the Investors, upon the terms and subject
to the conditions stated in this Agreement, shares (the “Shares”) of the Company’s common stock, $0.001 par
value per share (the “Common Stock”); and


 


C.
On July 4, 2021, the Company and Biosight Ltd., a company organized under the laws of the State of Israel (“Biosight”)
entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), pursuant to which a direct,
wholly owned subsidiary of the Company, Advaxis Ltd., will merge (the “Merger”) with and into Biosight, with Biosight
surviving as a wholly owned subsidiary of the Company, and the surviving company of the Merger. At the effective time of the Merger,
each of Biosight’s ordinary and preferred shares, par or nominal value NIS 0.01 per share, will be converted into the right to
receive a number of shares of the Common Stock equal to the exchange ratio, 118.2009 shares of Common Stock per Biosight share (subject
to adjustment to account for the proposed reverse stock split of the issued and outstanding Common Stock within a range, as determined
by the Company’s board of directors and agreed to by Biosight, of one new share of Advaxis common stock (the “Merged Company
Common Stock”) for every 10 to 30 shares (or any number in between) of outstanding Common Stock (the “Reverse Split”).


 


D.
Contemporaneously with the sale of the Shares hereunder, the parties hereto will execute and deliver a Registration Rights Agreement,
in the form attached hereto as Exhibit B (the “Registration Rights Agreement”), pursuant to which the Company
will agree to provide certain registration rights in respect of the Shares under the 1933 Act, and the rules and regulations promulgated
thereunder, and applicable state securities laws.


 


In
consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto agree as follows:


 




    	 



     


    

 


1.
Definitions. For the purposes of this Agreement, the following terms shall have the meanings set forth below:


 


“Affiliate”
means, with respect to any Person, any other Person which directly or indirectly through one or more intermediaries Controls, is controlled
by, or is under common Control with, such Person.


 


“Agreement”
has the meaning set forth in the Recitals.


 


“Biosight”
has the meaning set forth in the Recitals.


 


“Biosight
Information” has the meaning set forth in Section 5.19.


 


“Business
Day” means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of
business.


 


“Closing”
has the meaning set forth in Section 3.1.


 


“Closing
Date” has the meaning set forth in Section 3.1.


 


“Code”
has the meaning set forth in Section 4.21.


 


“Common
Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time shares
of Common Stock, including without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any
time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, shares of Common Stock.


 


“Company”
has the meaning set forth in the Recitals.


 


“Company’s
Knowledge” means the actual knowledge of the executive officers (as defined in Rule 405 under the 1933 Act) of the Company
and any executive officers of the Company’s Subsidiaries.


 


“Company
Stock Plan” has the meaning set forth in Section 4.3.


 


“Control”
(including the terms “controlling,” “controlled by” or “under common control with”) means the possession,
direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership
of voting securities, by contract or otherwise.


 


“Disclosure
Schedules” has the meaning set forth in Section 4.


 


“EDGAR
system” has the meaning set forth in Section 4.8.


 


“Environmental
Laws” has the meaning set forth in Section 4.20.


 


“ERISA”
has the meaning set forth in Section 4.21.


 


“FCPA”
means the Foreign Corrupt Practices Act of 1977, as amended.


 


“GAAP”
has the meaning set forth in Section 4.23.


 




    	2



     


    

 


“Intellectual
Property” has the meaning set forth in Section 4.19.


 


“Investor”
and “Investors” have the meanings set forth in the Recitals.


 


“Investor
Questionnaire” has the meaning set forth in Section 3.1.


 


“Material
Adverse Effect” means a material adverse effect on (i) the assets, liabilities, results of operations, condition (financial
or otherwise) or business of the Company and its Subsidiaries taken as a whole, (ii) the legality or enforceability of any of the Transaction
Documents or (iii) the ability of the Company to perform its obligations under the Transaction Documents; provided, however, that in
no event shall any of the following occurring after the date hereof, alone or in combination, be deemed to constitute, or be taken into
account in determining whether a Material Adverse Effect has occurred: (1) any adverse effect resulting directly or indirectly from general
business or economic conditions, except to the extent such general business or economic conditions have a materially disproportionate
effect on the Company as compared to companies in the Company’s industry, (2) any change in the Company’s stock price or
trading volume, or (3) any effect caused by the announcement or pendency of the transactions contemplated by the Transaction Documents,
or of the Merger, or the identity of any Investor or any of its Affiliates as the purchaser in connection with the transactions contemplated
by this Agreement or the Registration Rights Agreement.


 


“Material
Contract” means any contract, instrument or other agreement to which the Company is a party or by which it is bound which is
material to the business of the Company, and which has been filed an exhibit to the SEC Filings pursuant to Item 601(b)(10) of Regulation
S-K.


 


“Merged
Company Common Stock” has the meaning set forth in the Recitals.


 


“Merger”
has the meaning set forth in the Recitals.


 


“Merger
Agreement” has the meaning set forth in the Recitals.


 


“Nasdaq”
means the Nasdaq Stock Market, LLC.


 


“Options”
has the meaning set forth in Section 4.3.


 


“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint
venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed
herein.


 


“Placement
Agent” means Raymond James & Associates, Inc.


 


“Press
Release” has the meaning set forth in Section 9.7.


 


“Q3
2021 Form 10-Q” has the meaning set forth in Section 4.3.


 


“Registration
Rights Agreement” has the meaning set forth in the Recitals.


 


“Regulation
D” has the meaning set forth in the Recitals.


 




    	3



     


    

 


“Required
Investors” has the meaning set forth in the Registration Rights Agreement.


 


“Reverse
Split” has the meaning set forth in the Recitals.


 


“Schedule
of Investors” shall mean the Schedule of Investors attached hereto as Exhibit A.


 


“SEC”
has the meaning set forth in the Recitals.


 


“SEC
Filings” means the filings made by the Company pursuant to the 1933 Act or the 1934 Act.


 


“Share
Cap” has the meaning set forth in Section 2.2.


 


“Shares”
has the meaning set forth in the Recitals.


 


“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the 1934 Act.


 


“Subscription
Amount” means, as to an Investor, the aggregate amount to be paid for the Shares purchased hereunder as specified opposite
such Investor’s name on the Schedule of Investors, under the column entitled “Aggregate Purchase Price of Shares,”
in U.S. Dollars and in immediately available funds.


 


“Subsidiaries”
has the meaning set forth in Section 4.1.


 


“Trading
Day” means a day on which Nasdaq is open for trading.


 


“Transaction
Documents” means this Agreement and the Registration Rights Agreement.


 


“Transfer
Agent” has the meaning set forth in Section 7.7.


 


“USPTO”
has the meaning set forth in Section 4.19.


 


“VWAP
Price” has the meaning set forth in Section 2.1.


 


“1933
Act” has the meaning set forth in the Recitals.


 


“1934
Act” means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated
thereunder.


 


2.
Purchase and Sale of the Shares.


 


2.1.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company will issue and sell, and the Investors
will purchase, severally and not jointly, the number of Shares set forth opposite the name of such Investor under the heading “Number
of Shares to be Purchased” on the Schedule of Investors (subject to adjustment pursuant to Section 2.2 hereof) at a price per Share
equal to be valued at a price equal to the average of the VWAP Prices of the Common Stock (which shall be adjusted, as appropriate, to
reflect the effect of the Reverse Split) on the five (5) consecutive Trading Days ending with the Trading Day immediately prior to the
Closing Date. The “VWAP Price” for any Trading Day shall be the volume-weighted average price of the Common Stock
on Nasdaq for such Trading Day; provided, that if the Common Stock is not listed on Nasdaq on any such Trading Market for any
such Trading Day, then the price used for such Trading Day shall be the average of the highest closing bid price and the lowest closing
ask price of any of the market makers for such security as reported in the OTCQX, OTCQB, Pink or Grey markets (in that order) operated
by OTCMarkets.


 




    	4



     


    

 


2.2.
In compliance with Nasdaq Rule 5635(d), the Company shall not issue or sell, pursuant to this Agreement and the Securities Purchase Agreements
being entered into on the date hereof with other investors, an aggregate number of shares of the Common Stock that shall represent more
than 19.99% of the outstanding shares of Common Stock or the voting power of the Company on a post-transaction as of the date of such
issuances (the “Share Cap”). For the avoidance of doubt, since the Closing shall not occur until after the Merger
and Reverse Split have been effected, the number of outstanding shares of Common Stock and the voting power of the Company shall be calculated
on a post-Merger, post-Reverse Split basis. If the aggregate number of shares of the Common Stock that would otherwise be sold pursuant
to this Agreement and the Securities Purchase Agreements being entered into on the date hereof with other investors would exceed the
Share Cap, then the number of shares of Common Stock saleable pursuant to this Agreement and all other such agreements shall be reduced
proportionately such that the total number of shares of Common Stock to be so sold shall equal the Share Cap.


 


3.
Closing.


 


3.1.
The closing of the purchase and sale of the Shares (which Shares are set forth in the Schedule of Investors) pursuant to this Agreement
(the “Closing”) shall occur remotely via exchange of documents and signatures at a time to be agreed to by the Company
and the Investors (the “Closing Date”), but in no event later than the second Trading Day after the date hereof, and
of which the Investors will be notified in advance by the Placement Agent. At or prior to the Closing, each Investor shall execute any
related agreements or other documents required to be executed hereunder, dated on or before the Closing Date, including but not limited
to the Investor Questionnaire in the form attached hereto as Exhibit C (the “Investor Questionnaire”).


 


3.2.
On the Closing Date, each Investor shall deliver or cause to be delivered to the Company the Subscription Amount via wire transfer of
immediately available funds pursuant to the wire instructions delivered to such Investor by the Company on or prior to the Closing Date.


 


3.3.
At or before the Closing, the Company shall deliver or cause to be delivered to each Investor a number of Shares, registered in the name
of the Investor, in the amount set forth opposite the name of such Investor under the heading “Number of Shares to be Purchased”
on the Schedule of Investors. The Shares shall be issued in book entry form.








 




    	5



     


    

 





4. Representations and Warranties
of the Company. The Company hereby represents and warrants to the Investors that, except as set forth in the schedules delivered herewith
(collectively, the “Disclosure Schedules”) and except as otherwise described in the SEC Filings, which qualify these
representations and warranties in their entirety: 


 


4.1.
Organization, Good Standing and Qualification. The Company is an entity duly incorporated, validly existing and in good standing
under the laws of the State of Delaware, with the requisite corporate power and authority to own or lease and use its properties and
assets, to execute and deliver the Transaction Documents, to carry out the provisions of the Transaction Documents, to issue and sell
the Shares (assuming the consummation prior thereto of the Reverse Split) and to carry on its business as presently conducted as described
in the SEC Filings. Each Person of which the Company owns, directly or indirectly, an amount of the voting securities, other voting ownership
or voting partnership interests which is sufficient to elect at least a majority of such Person’s Board of Directors or other governing
body (or, if there are no such voting interests, 50% or more of the equity interests of which) identified in the Disclosure Schedules
(all such Persons, the “Subsidiaries”) is an entity duly incorporated or otherwise organized, validly existing and
in good standing (to the extent such concept exists in the relevant jurisdiction) under the laws of the jurisdiction of its incorporation
or organization, as applicable, and has all requisite power and authority to carry on its business to own and use its properties. Neither
the Company nor any of its Subsidiaries is in violation or default in any material respect of any of the provisions of its respective
articles of association, charter, certificate of incorporation, bylaws, limited partnership agreement or other organizational or constitutive
documents. Each of the Company and its Subsidiaries is duly qualified to do business as a foreign entity and is in good standing (to
the extent such concept exists in the relevant jurisdiction) in each jurisdiction in which the conduct of its business or its ownership
or leasing of property makes such qualification necessary, except to the extent any failure to so qualify has not had and would not reasonably
be expected to have a Material Adverse Effect.


 


4.2.
Authorization. The Company has the requisite corporate power and authority and has taken all requisite corporate action necessary
for, and (assuming the consummation prior thereto of the Reverse Split) no further action on the part of the Company, its officers, directors
and stockholders is necessary for, (i) the authorization, execution and delivery of the Transaction Documents, (ii) the authorization
of the performance of all obligations of the Company hereunder or thereunder, and (iii) the authorization, issuance and delivery of the
Shares. Each of the Transaction Documents has been duly executed and delivered by the Company and, assuming due authorization, execution
and delivery by the Investors, constitute valid and binding obligations of the Company enforceable in accordance with their terms, except
(a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement
of creditors’ rights, (b) general principles of equity that restrict the availability of equitable remedies and (c) to the extent
that the enforceability of indemnification provisions may be limited by applicable laws.


 


4.3.
Capitalization. The Company has an authorized and outstanding capitalization as set forth in its Quarterly Report on Form 10-Q
for the fiscal quarter ended July 31, 2021 (the “Q3 2021 Form 10-Q”) as of the dates set forth therein. The shares
of Common Stock outstanding prior to the issuance of the Shares have been duly authorized and are validly issued, fully paid and non-assessable.
Except as described in the Q3 2021 Form 10-Q, there are no options, warrants, agreements, contracts or other rights in existence to purchase
or acquire from the Company or any Subsidiary of the Company any shares of the capital stock of the Company or any Subsidiary of the
Company, subject to the grant of options consistent with past practices. The description of the Company’s stock option, stock bonus
and other stock plans or arrangements (the “Company Stock Plans”), and the options (the “Options”)
or other rights granted thereunder, set forth in the SEC Filings accurately and fairly presents in all material respects the information
required to be shown with respect to such plans, arrangements, options and rights. Each grant of an Option (A) was duly authorized no
later than the date on which the grant of such Option was by its terms to be effective by all necessary corporate action, including,
as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required
shareholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was
duly executed and delivered by each party thereto and (B) was made in accordance with the terms of the applicable Company Stock Plan,
and all applicable laws and regulatory rules or requirements, including all applicable federal securities laws.


 




    	6



     


    

 


4.4.
Valid Issuance. The Shares have been duly and validly authorized and, when issued and paid for pursuant to this Agreement, and
assuming the consummation prior to the issuance thereof of the Reverse Split, will be validly issued, fully paid and nonassessable, and
shall be free and clear of all encumbrances and restrictions (other than those created by the Investors), except for restrictions on
transfer set forth in the Transaction Documents or imposed by applicable securities laws.


 


4.5.
No Transfer Taxes or Duties. No stamp, documentary, issuance, registration, transfer, withholding, capital gains, income or other
taxes or duties are payable by or on behalf of the Investors, the Company or any of its Subsidiaries to any taxing authority thereof
or therein in connection with (i) the execution, delivery or consummation of this Agreement, (ii) the creation, allotment and issuance
of the Shares, or (iii) the sale and delivery of the Shares to the Investors.


 


4.6.
Other Registration Rights. Neither the offering or sale of the Shares as contemplated by this Agreement nor the filing of the
Registration Statement contemplated by the Registration Rights Agreement gives rise to any rights for or relating to the registration
of any shares of Common Stock or other securities of the Company, that have not been waived. Except as described in the SEC filings and
except as provided in the Registration Rights Agreement, no Person has the right to require the Company to register any securities of
the Company under the 1933 Act, whether on a demand basis or in connection with the registration of securities of the Company for its
own account or for the account of any other Person.


 


4.7.
Consents. The execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale
of the Shares require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official other
than filings that have been made pursuant to applicable state securities laws, the requisite filings with the Secretary of State of the
State of Delaware in order to effect the Reverse Split, post-sale filings pursuant to applicable state and federal securities laws and
the rules and regulations of Nasdaq, which the Company undertakes to file within the applicable time periods, and other than the registration
statement required to be filed by the Registration Rights Agreement.


 


4.8.
Delivery of SEC Filings. True and complete copies of the SEC Filings have been made available by the Company to the Investors
through the Electronic Data Gathering, Analysis, and Retrieval system (the “EDGAR system”) (other than any information
for which the Company has received confidential treatment from the SEC).


 




    	7



     


    

 


4.9.
No Material Adverse Change. Since July 31, 2021, except as specifically set forth in a subsequent SEC Filing, there has not been:


 


(i)
any change in the assets, liabilities, financial condition or operating results of the Company from that reflected in the financial statements
included in the Q3 2021 Form 10-Q, except for changes in the ordinary course of business which have not had and would not reasonably
be expected, individually or in the aggregate, to have a Material Adverse Effect;


 


(ii)
any declaration or payment by the Company of any dividend, or any authorization or payment by the Company of any distribution, on any
of the capital stock of the Company, or any redemption or repurchase by the Company of any securities of the Company;


 


(iii)
any material damage, destruction or loss, whether or not covered by insurance, to any assets or properties of the Company;


 


(iv)
any waiver, not in the ordinary course of business, by the Company of a material right or of a material debt owed to it;


 


(v)
any satisfaction or discharge of any lien, claim or encumbrance or payment of any obligation by the Company, except in the ordinary course
of business;


 


(vi)
any change or amendment to the Company’s Certificate of Incorporation or Bylaws, or termination of or material amendment to any
contract of the Company that the Company is required to file with the SEC pursuant to Item 601(b)(10) of Regulation S-K;


 


(vii)
any material labor difficulties or, to the Company’s Knowledge, labor union organizing activities with respect to employees of
the Company;


 


(viii)
any material transaction entered into by the Company other than in the ordinary course of business;


 


(ix)
the loss of the services of any executive officer (as defined in Rule 405 under the 1933 Act) of the Company; or


 


(x)
any other event or condition that, to the Company’s Knowledge, has had or would reasonably be expected to have a Material Adverse
Effect.


 


4.10.
SEC Filings. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company
under 1933 Act and the 1934 Act, including pursuant to Section 13(a) or 15(d) thereof, for the one year preceding the date hereof (or
such shorter period as the Company was required by law or regulation to file such material). At the time of filing thereof, the SEC Filings
complied as to form in all material respects with the requirements of the 1933 Act or 1934 Act, as applicable, and did not contain any
untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the
statements made therein, in the light of the circumstances under which they were made, not misleading.


 




    	8



     


    

 


4.11.
No Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction Documents by the Company
and the issuance and sale of the Shares in accordance with the provisions thereof will not (i) conflict with or result in a breach or
violation of (a) assuming the consummation prior thereto of the Reverse Split, any of the terms and provisions of, or constitute a default
under, the Company’s Certificate of Incorporation or Bylaws, both as in effect on the date hereof (true and complete copies of
which have been made available to the Investors through the EDGAR system), or (b) assuming the accuracy of the representations and warranties
in Section 5, any applicable statute, rule, regulation or order of any governmental agency or body or any court, domestic or foreign,
having jurisdiction over the Company or its Subsidiaries, or any of their assets or properties, or (ii) conflict with, or constitute
a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any lien, encumbrance
or other adverse claim upon any of the properties or assets of the Company or its Subsidiaries or give to others any rights of termination,
amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any Material Contract except, in the case
of clauses (i)(b) and (ii) only, for such conflicts, breaches, violations and defaults as have not and would not reasonably be expected
to have a Material Adverse Effect. This Section does not relate to matters with respect to tax status, which are the subject of Section
4.13, labor matters, which are the subject of Section 4.16, intellectual property, which are the subject of Section 4.19, environmental
laws, which are the subject of Section 4.20, and ERISA matters, which are the subject of Section 4.21.


 


4.12.
Compliance. The Company and each of its Subsidiaries is not (i) in default under or in violation of (and no event has occurred
that has not been waived that, with notice or lapse of time or both, would result in a default by the Company under), nor has the Company
received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any
other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or
violation has been waived) or (ii) in violation of any statute, rule, ordinance or regulation of any governmental authority, including
without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety,
product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result
in a Material Adverse Effect. The Company and each of its Subsidiaries has operated and currently is in compliance in all material respects
with all applicable laws, rules and regulations of the jurisdictions in which it is conducting business. The Company and each of its
Subsidiaries: (i) is and at all times has been in material compliance with all statutes, rules or regulations applicable to the ownership,
testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage,
import, export or disposal of any product under development, manufactured or distributed by the Company (“Applicable Laws”);
(ii) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other written correspondence or
notice from the U.S. Food and Drug Administration (the “FDA”) or any other federal, state, local or foreign governmental
or regulatory authority alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals,
clearances, authorizations, permits and supplements or amendments thereto required by any Applicable Laws to conduct the Company’s
business as described in the SEC Filings (“Authorizations”); (iii) possesses all material Authorizations and such
Authorizations are valid and in full force and effect and the Company is not in material violation of any such Authorizations; (iv) has
not received notice of any pending or completed claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or
other action from the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party alleging
that any product operation or activity is in material violation of any Applicable Laws or Authorizations and the Company has no knowledge
that the FDA or any other federal, state, local or foreign governmental or regulatory authority or third party is considering any such
claim, litigation, arbitration, action, suit, investigation or proceeding; (v) has not received notice that the FDA or any other federal,
state, local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify
or revoke any material Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or
regulatory authority is considering such action; and (vi) has filed, obtained, maintained or submitted all material reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations
and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially
complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); (vii) neither the Company nor,
to the Company’s Knowledge, any of its officers, directors or managing employees (as defined in 42 U.S.C. § 1320a-5(b)) is
or has been excluded, suspended or debarred from participation in any state or federal health care program, or made subject to any pending
or, to the Company’s Knowledge, threatened or contemplated action which could reasonably be expected to result in such exclusion,
suspension or debarment and (viii) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated,
conducted or issued, any recall, market withdrawal or replacement, safety alert, “dear doctor” letter, or other notice or
action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the Company’s
Knowledge, no third party has initiated, conducted or intends to initiate any such notice or action.


 




    	9



     


    

 


4.13.
Tax Matters. The Company and its Subsidiaries have filed all tax returns required to have been filed by the Company or its Subsidiaries
with all appropriate governmental agencies and have paid all taxes shown thereon or otherwise owed by them. The Company has made adequate
charges, accruals and reserves in the applicable financial statements referred to in Section 4.23 below in respect of all federal, state
and foreign income and franchise taxes for all periods as to which the tax liability of the Company or its Subsidiaries has not been
finally determined, except to the extent of any inadequacy that would not reasonably be expected to result in a Material Adverse Effect.
There are no material tax liens or claims pending or, to the Company’s Knowledge, threatened against the Company or any of its
Subsidiaries or any of their respective material assets or property.


 


4.14.
Title to Properties. The Company and its Subsidiaries have good and marketable title to all real properties and all other tangible
properties and assets owned by them, in each case free from liens, encumbrances and defects, except such as would not reasonably be expected,
individually or in the aggregate, to have a Material Adverse Effect; and the Company and its Subsidiaries hold any leased real or personal
property under valid, subsisting and enforceable leases with which the Company are in compliance and with no exceptions, except such
as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.








 


4.15.
Certificates, Authorities and Permits. The Company and its Subsidiaries possess all certificates, authorizations and permits issued
by the appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses, except where failure
to obtain such certificates, authorizations and permits would not reasonably be expected to have a Material Adverse Effect, and neither
the Company nor its Subsidiaries has received any notice of proceedings relating to the revocation or modification of any such certificate,
authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a
Material Adverse Effect.


 


4.16.
Labor Matters. No material labor dispute with the employees of the Company or any of its Subsidiaries exists, or, to the Company’s
Knowledge, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any
of its principal suppliers, manufacturers or contractors that would be reasonably likely to have a Material Adverse Effect.


 


4.17.
Foreign Corrupt Practices. (i) None of the Company or any of its Subsidiaries or Affiliates, or any director or officer thereof,
or, to the Company’s Knowledge, any employee, agent or representative of the Company or any of its Subsidiaries or Affiliates,
has taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment, giving
or receipt of money, property, gifts or anything else of value, directly or indirectly, to any government official (including any officer
or employee of a government or government-owned or controlled entity or of a public international organization, or any person acting
in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political
office) (“Government Official”) in order to influence official action, or to any person in violation of any applicable
anti-corruption laws; (ii) the Company and its subsidiaries and their respective Affiliates have conducted their businesses in compliance
with applicable anti-corruption laws and have instituted and maintained and will continue to maintain policies and procedures reasonably
designed to promote and achieve compliance with such laws and with the representations and warranties contained herein; and (iii) neither
the Company nor its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment,
promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of any applicable
anti-corruption laws.


 


4.18.
Anti-Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in material
compliance with all applicable financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended
by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act
of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries
conduct business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered
or enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding
by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with
respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened...


 




    	10



     


    

 


4.19.
Intellectual Property.


 


(a)
The Company and its Subsidiaries own or have existing licenses under all patents, patent applications, patent rights, licenses, inventions,
copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems
or procedures), trademarks, service marks, trade names and other intellectual property used in or necessary for the conduct of the business
of the Company and its Subsidiaries, in the manner described in the SEC Filings (collectively, the “Intellectual Property”),
and such licenses are enforceable against the Company and, to the Company’s Knowledge, enforceable against the counterparties to
the license agreements under which such licenses were granted to the Company, except as certain rights under any licenses may be limited
by bankruptcy and other similar laws affecting the rights of creditors generally and general principles of equity; to the Company’s
Knowledge, the patents, trademarks, and copyrights, if any, included within the Intellectual Property are valid, enforceable, and subsisting.


 


(b)
Except as set forth in the SEC Filings, (i) neither the Company nor any of its Subsidiaries is obligated to pay a material royalty, grant
a license to, or provide other material consideration to any third party in connection with the Intellectual Property, (ii) neither the
Company nor any of its Subsidiaries has received any written notice of any claim of infringement, misappropriation of or conflict with
asserted rights of others with respect to any of the Company’s or its Subsidiaries’ product candidates, processes or Intellectual
Property, (iii) to the Company’s Knowledge, with the exception of the review of pending applications in the United States Patent
and Trademark Office (“USPTO”) or corresponding foreign patent offices, no action, suit, claim or other proceeding
is pending or, to the Company’s Knowledge, is threatened, challenging the Company’s or any of its Subsidiaries’ rights
in or to any Intellectual Property, or challenging the validity, enforceability or scope of any Intellectual Property, (iv) to the Company’s
Knowledge, none of the development, manufacture, sale or use of any of the discoveries, inventions, product candidates or processes of
the Company in the manner presently contemplated by the Company and referred to in the SEC Filings do or will infringe, or violate any
right or issued patent claim of any third party in any material respect, (v) to the Company’s Knowledge, no third party has any
ownership right in or to any Intellectual Property that is owned by the Company, other than any co-owner of any patent constituting Intellectual
Property who is listed on the records of the USPTO and any co-owner of any patent application constituting Intellectual Property who
is named in such patent application, (vi) except as would not, individually or in the aggregate, have a Material Adverse Effect, the
Intellectual Property owned by the Company and its Subsidiaries is free and clear of all liens or encumbrances, (vii) to the Company’s
Knowledge, none of the Intellectual Property employed by the Company or its Subsidiaries in the conduct of the business in the manner
described in the SEC Filings has been obtained or is being used by the Company or its Subsidiaries in material violation of any contractual
obligation binding on the Company or, to the Company’s Knowledge, upon any of its officers, consultants, directors or employees,
and (viii) the Company has taken reasonable measures to protect its confidential information and trade secrets and to maintain and safeguard
the Intellectual Property.


 


4.20.
Environmental Matters. Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect, neither the Company nor any of its Subsidiaries is in violation of any statute, rule, regulation, decision or order of any governmental
agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or relating
to the protection or restoration of the environment or human exposure to hazardous or toxic substances (collectively, “Environmental
Laws”), has released any hazardous substances regulated by Environmental Law on to any real property that it owns or operates,
or has received any written notice or claim it is liable for any off-site disposal or contamination pursuant to any Environmental Laws;
and to the Company’s Knowledge, there is no pending or threatened investigation that would reasonably be expected to lead to such
a claim.


 




    	11



     


    

 


4.21.
ERISA. Except as would not, individually or in the aggregate, have (or reasonably be expected to have) a Material Adverse Effect,
each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”)
that the Company or any member of its “Controlled Group” (defined as any organization which is under common control with
the Company within the meaning of Section 414 of the Internal Revenue Code of 1986, as amended (the “Code”)) sponsors
or maintains has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations,
including but not limited to ERISA and the Code.


 


4.22.
Legal Proceedings. There are no legal or governmental proceedings pending or, to the Company’s Knowledge, threatened to
which the Company or any of its Subsidiaries is a party or to which any of the properties of the Company or any of its Subsidiaries is
subject (i) other than proceedings accurately described in all material respects in the SEC Filings and proceedings that, individually
or in the aggregate, would not reasonably be expected to have a Material Adverse Effect or (ii) that are required to be described in
the SEC Filings and are not so described in all material respects; and there are no statutes, regulations, contracts or other documents
that are required to be described in the SEC Filings or to be filed as exhibits to the SEC Filings that are not described in all material
respects or filed as required.


 


4.23.
Financial Statements. The financial statements included in each SEC Filing comply in all material respects with applicable accounting
requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected
by a subsequent restatement) and present fairly, in all material respects, the financial position of the Company as of the dates shown
and its results of operations and cash flows for the periods shown, subject in the case of unaudited financial statements to normal,
immaterial year-end audit adjustments, and such financial statements have been prepared in conformity with United States generally accepted
accounting principles applied on a consistent basis during the periods involved (“GAAP”) (except as may be disclosed therein
or in the notes thereto, and except that the unaudited financial statements may not contain all footnotes required by GAAP, and, in the
case of quarterly financial statements, as permitted by Form 10-Q under the 1934 Act).


 


4.24.
Insurance Coverage. The Company and each of the Subsidiaries maintain insurance covering their respective properties, operations,
personnel and businesses as the Company reasonably deems adequate; the Company reasonably believes such insurance insures against such
losses and risks in accordance with customary industry practice to protect the Company and the Subsidiaries and their respective businesses
and which is commercially reasonably for the current conduct of its business; all such insurance is fully in force on the date hereof.


 




    	12



     


    

 


4.25.
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements.
There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing
of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable
basis for, the delisting of the Common Stock from Nasdaq.


 


4.26.
Brokers and Finders. Other than the Placement Agent, no Person will have, as a result of the transactions contemplated by the
Transaction Documents, any valid right, interest or claim against or upon the Company or an Investor for any commission, fee or other
compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company. No Investor shall have
any obligation with respect to any fees, or with respect to any claims made by or on behalf of other Persons for fees, in each case of
the type contemplated by this Section 4.26 that may be due in connection with the transactions contemplated by this Agreement or the
Transaction Documents.


 


4.27.
No Directed Selling Efforts or General Solicitation. Neither the Company nor any of its Subsidiaries nor any Person acting on
its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D) in connection with
the offer or sale of any of the Shares. The Company has offered the Shares for sale only to the Investors and certain other “accredited
investors” within the meaning of Rule 501 under the 1933 Act.


 


4.28.
No Integrated Offering. Neither the Company nor any of its Subsidiaries nor any Person acting on its behalf has, directly or indirectly,
made any offers or sales of any Company security or solicited any offers to buy any Company security, under circumstances that would
adversely affect reliance by the Company on Section 4(a)(2) for the exemption from registration for the transactions contemplated hereby
or would require registration of the Shares under the 1933 Act.


 


4.29.
Private Placement. Assuming the accuracy of the representations and warranties of the Investors set forth in Section 5, the offer
and sale of the Shares to the Investors as contemplated hereby is exempt from the registration requirements of the 1933 Act.


 


4.30.
Questionable Payments. Neither the Company nor any of its Subsidiaries nor, to the Company’s Knowledge, any of the current
or former directors, officers, employees, agents or other Persons acting on behalf of the Company or its Subsidiaries, has on behalf
of the Company or its Subsidiaries: (a) used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses
relating to political activity; (b) made any direct or indirect unlawful payments to any governmental officials or employees from corporate
funds; (c) established or maintained any unlawful or unrecorded fund of corporate monies or other assets which is in violation of law;
(d) made any false or fictitious entries on the books and records of the Company; or (e) made any unlawful rebate, payoff, influence
payment, kickback, bribe or other unlawful payment of any nature or (f) violated or is in violation of any provision of the Foreign Corrupt
Practices Act of 1977, as amended.


 




    	13



     


    

 


4.31.
Transactions with Affiliates. Except with respect to the purchase of shares of Common Stock substantially concurrent with the
purchase of Shares under the Transaction Documents and for a price per share no less than the purchase price per Share set forth in Section
2 hereof, or as disclosed in the SEC Filings, none of the officers or directors of the Company and, to the Company’s Knowledge,
none of the employees of the Company is presently a party to any transaction with the Company or any Subsidiary (other than as holders
of stock options and/or warrants, and for services as employees, officers and directors), including any contract, agreement or other
arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise
requiring payments to or from any officer, director or such employee or, to the Company’s Knowledge, any entity in which any officer,
director, or any such employee has a substantial interest or is an officer, director, trustee or partner.


 


4.32.
Internal Controls. The Company is in material compliance with the provisions of the Sarbanes-Oxley Act of 2002 currently applicable
to the Company. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance
that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access
to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability
for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals and appropriate action is taken
with respect to any differences. The Company has established disclosure controls and procedures (as defined in 1934 Act Rules 13a-15(e)
and 15d-15(e)) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the
Company, including the Subsidiaries, is made known to the certifying officers by others within those entities, particularly during the
period in which the Company’s most recently filed periodic report under the 1934 Act, as the case may be, is being prepared. The
Company has established internal control over financial reporting (as defined in 1934 Act Rules 13a-15(f) and 15d-15(f)) to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with GAAP. The Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures
and the Company’s internal control over financial reporting (collectively, “internal controls”) as of the end
of the period covered by the most recently filed periodic report under the 1934 Act (such date, the “Evaluation Date”). The
Company presented in its most recently filed periodic report under the 1934 Act the conclusions of the certifying officers about the
effectiveness of such internal controls based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been
no significant changes in the Company’s internal controls or, to the Company’s Knowledge, in other factors that could significantly
affect the Company’s internal controls. The Company maintains and will continue to maintain a standard system of accounting established
and administered in accordance with GAAP and the applicable requirements of the 1934 Act.


 


4.33.
Investment Company. The Company is not required to register as an “investment company” as such term is defined in
the Investment Company Act of 1940, as amended.


 




    	14



     


    

 


4.34.
Tests and Preclinical and Clinical Trials. The studies, tests and preclinical and clinical trials conducted by the Company that
are described in the SEC Filings, and, to the Company’s Knowledge, those studies, tests and preclinical and clinical trials conducted
on behalf of the Company, were and, if still pending, are being conducted in all material respects in accordance with experimental protocols,
procedures and controls pursuant to accepted professional scientific standards and all Applicable Laws and Authorizations, including,
without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder; the descriptions of
the results of such studies, tests and trials contained in the SEC Filings are accurate and complete and fairly present the data derived
from such studies, tests and trials in all material respects; the Company is not aware of any studies, tests or trials, the results of
which the Company believes are materially inconsistent with the study, test or trial results described or referred to in the SEC Filings
when viewed in the context in which such results are described and the clinical state of development; and the Company has not received
any notices or written correspondence from the FDA or any other federal, state, local or foreign governmental or regulatory authority
requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or
on behalf of the Company.


 


4.35.
Manipulation of Price. The Company has not, and, to the Company’s Knowledge, no Person acting on its behalf has taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of any of the Shares.


 


4.36.
Bad Actor Disqualification. None of the Company, any predecessor or affiliated issuer of the Company nor, to the Company’s
Knowledge, any director or executive officer of the Company or any promoter connected with the Company in any capacity, is subject to
any of the “bad actor” disqualifications within the meaning of Rule 506(d) under the 1933 Act, except for a disqualification
event covered by Rule 506(d)(2) or (d)(3).


 


4.37.
Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor, to the Company’s Knowledge, any other Person acting on its behalf has provided any of
the Investors with any information that it believes constitutes material, non-public information that will not otherwise be disclosed
in the SEC Filings on or prior to the Closing Date. The Company understands and confirms that the Investors will rely on the foregoing
representation in effecting transactions in securities of the Company.


 


4.38.
Required Filings. Except for the transactions contemplated by this Agreement, including the acquisition of the Shares contemplated
hereby and the use of proceeds contemplated hereby, no event or circumstance has occurred or information exists with respect to the Company
or its business, properties, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure
or announcement by the Company but which has not been so publicly announced or disclosed.


 


4.39.
General. No representation or warranty by the Company in this Agreement or any certificate or other document furnished or to be
furnished to Investor pursuant to this Agreement contains any untrue statement of a material fact, or omits to state a material fact
necessary to make the statements contained therein, in light of the circumstances in which they are made, not misleading. To the Company’s
Knowledge, there is no event or circumstance that the Company has not disclosed to Investor which could reasonably be expected to have
a Material Adverse Effect.


 




    	15



     


    

 


4.40.
Acknowledgement Regarding Investors’ Trading Activity. The Company acknowledges and agrees that (i) none of the Investors
has been asked to agree, nor has any Investor agreed, to desist from purchasing or selling, long and/or short, securities of the Company,
or “derivative” securities based on securities issued by the Company or to hold the Shares for any specified term; (ii) any
Investor, and counter-parties in “derivative” transactions to which any such Investor is a party, directly or indirectly,
presently may have a “short” position in the Shares, and (iii) each Investor shall not be deemed to have any affiliation
with or control over any arm’s length counter-party in any “derivative” transaction. The Company further understands
and acknowledges that one or more Investors may engage in hedging and/or trading activities at various times during the period that the
Shares are outstanding and (b) such hedging and/or trading activities, if any, can reduce the value of the existing stockholders’
equity interest in the Company both at and after the time the hedging and/or trading activities are being conducted. The Company acknowledges
that such aforementioned hedging and/or trading activities do not constitute a breach of this Agreement or any of the documents executed
in connection herewith.


 


5.
Representations and Warranties of the Investors. Each of the Investors hereby severally, and not jointly, represents and warrants
to the Company that:


 


5.1.
Organization and Existence. Such Investor is a validly existing corporation, limited partnership or limited liability company
and has all requisite corporate, partnership or limited liability company power and authority to enter into and consummate the transactions
contemplated by the Transaction Documents and to carry out its obligations hereunder and thereunder, and to invest in the Shares pursuant
to this Agreement.


 


5.2.
Authorization. The execution, delivery and performance by such Investor of the Transaction Documents to which such Investor is
a party have been duly authorized and each has been duly executed and when delivered will constitute the valid and legally binding obligation
of such Investor, enforceable against such Investor in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent
transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally.


 


5.3.
Purchase Entirely for Own Account. The Shares to be received by such Investor hereunder will be acquired for such Investor’s
own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the 1933
Act, and such Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in violation
of the 1933 Act without prejudice, subject however, to such Investor’s right at all times to sell or otherwise dispose of all or
any part of such Shares in compliance with applicable federal and state securities laws. Nothing contained herein shall be deemed
a representation or warranty by such Investor to hold the Shares for any period of time. Such Investor is not a broker-dealer registered
with the SEC under the 1934 Act or an entity engaged in a business that would require it to be so registered.


 


5.4.
Investment Experience. Such Investor acknowledges that it can bear the economic risk and complete loss of its investment in the
Shares and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of
the investment contemplated hereby.


 




    	16



     


    

 


5.5.
Disclosure of Information. Such Investor has had an opportunity to receive, review and understand all information related to the
Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms
and conditions of the offering of the Shares, and has conducted and completed its own independent due diligence. Such Investor acknowledges
receipt of copies of the SEC Filings. Based on the information such Investor has deemed appropriate, and without reliance upon the Placement
Agent, it has independently made its own analysis and decision to enter into the Transaction Documents. Such Investor is relying exclusively
on its own investment analysis and due diligence (including professional advice it deems appropriate) with respect to the execution,
delivery and performance of the Transaction Documents, the Shares and the business, condition (financial and otherwise), management,
operations, properties and prospects of the Company, including but not limited to all business, legal, regulatory, accounting, credit
and tax matters. Neither such inquiries nor any other due diligence investigation conducted by such Investor shall modify, limit or otherwise
affect such Investor’s right to rely on the Company’s representations and warranties contained in this Agreement.


 


5.6.
Restricted Securities. Such Investor understands that the Shares are characterized as “restricted securities” under
the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering
and that under such laws and applicable regulations such securities may be resold without registration under the 1933 Act only in certain
limited circumstances.


 


5.7.
Legends. It is understood that, except as provided below, certificates or book entry accounts evidencing the Shares may bear the
following or any similar legend:


 


“The
securities represented hereby have not been registered with the Securities and Exchange Commission or the securities commission of any
state in reliance upon an exemption from registration under the Securities Act of 1933, as amended, and, accordingly, may not be transferred
unless (i) such securities have been registered for sale pursuant to the Securities Act of 1933, as amended, (ii) such securities may
be sold pursuant to Rule 144, or (iii) the Company has received an opinion of counsel reasonably satisfactory to it that such transfer
may lawfully be made without registration under the Securities Act of 1933, as amended. NOTWITHSTANDING THE FOREGOING, THE SECURITIES
MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”



 


If
required by the authorities of any state in connection with the issuance of sale of the Shares, the legend required by such state authority.


 




    	17



     


    

 


5.8.
Accredited Investor. Such Investor is an “accredited investor” within the meaning of Rule 501 under the 1933 Act and
has executed and delivered to the Company an Investor Questionnaire with respect to such Investor, which such Investor represents and
warrants is true, correct and complete. Such investor is a sophisticated institutional investor with sufficient knowledge and experience
in investing in private equity transactions to properly evaluate the risks and merits of its purchase of the Shares. Such Investor has
determined based on its own independent review and such professional advice as it deems appropriate that its purchase of the Shares and
participation in the transactions contemplated by the Transaction Documents (i) are fully consistent with its financial needs, objectives
and condition, (ii) comply and are fully consistent with all investment policies, guidelines and other restrictions applicable to such
Investor, (iii) have been duly authorized and approved by all necessary action, and (iv) are a fit, proper and suitable investment for
such Investor, notwithstanding the substantial risks inherent in investing in or holding the Shares.


 


5.9.
Placement Agent. Such Investor hereby acknowledges and agrees that (a) the Placement Agent is acting solely as placement agent
in connection with the execution, delivery and performance of the Transaction Documents and is not acting as an underwriter or in any
other capacity and is not and shall not be construed as a fiduciary for such Investor, the Company or any other person or entity in connection
with the execution, delivery and performance of the Transaction Documents, (b) the Placement Agent has not made nor will it make any
representation or warranty, whether express or implied, of any kind or character and has not provided any advice or recommendation in
connection with the execution, delivery and performance of the Transaction Documents, (c) the Placement Agent will not have any responsibility
with respect to (i) any representations, warranties or agreements made by any person or entity under or in connection with the execution,
delivery and performance of the Transaction Documents, or the execution, legality, validity or enforceability (with respect to any person)
thereof, or (ii) the business, affairs, financial condition, operations, properties or prospects of, or any other matter concerning the
Company, and (d) the Placement Agent will not have any liability or obligation (including without limitation, for or with respect to
any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by such
Investor, the Company or any other person or entity), whether in contract, tort or otherwise, to such Investor, or to any person claiming
through it, in respect of the execution, delivery and performance of the Transaction Documents.


 


5.10.
No General Solicitation. Such Investor did not learn of the investment in the Shares as a result of any general solicitation or
general advertising.


 


5.11.
Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid
right, interest or claim against or upon the Company or an Investor for any commission, fee or other compensation pursuant to any agreement,
arrangement or understanding entered into by or on behalf of such Investor.


 


5.12.
Short Sales and Confidentiality Prior to the Date Hereof. Such Investor has not, nor has any Person acting on behalf of or pursuant
to any understanding with such Investor, directly or indirectly executed any purchases or sales, including Short Sales, of the securities
of the Company during the period commencing as of the time that such Investor was first contacted by the Company, the Placement Agent
or any other Person regarding the transactions contemplated hereby and ending immediately prior to the date hereof. Other than to other
Persons party to this Agreement, such Investor has maintained the confidentiality of all disclosures made to it in connection with this
transaction (including the existence and terms of this transaction).


 




    	18



     


    

 


5.13.
No Government Recommendation or Approval. Such Investor understands that no United States federal or state agency, or similar
agency of any other country, has reviewed, approved, passed upon, or made any recommendation or endorsement of the Company or the purchase
of the Shares.


 


5.14.
No Intent to Effect a Change of Control; Ownership. Such Investor has no present intent to effect a “change of control”
of the Company as such term is understood under the rules promulgated pursuant to Section 13(d) of the 1934 Act. Except as set forth
on Schedule 5.14 hereto, as of the date hereof, neither the Investor nor any of its Affiliates is the owner of record or the beneficial
owner of shares of Common Stock or securities convertible into or exchangeable for Common Stock.


 


5.15.
No Conflicts. The execution, delivery and performance by such Investor of the Transaction Documents and the consummation by such
Investor of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of such
Investor or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default)
under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument
to which such Investor is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including
federal and state securities laws) applicable to such Investor, except in the case of clauses (ii) and (iii) above, for such conflicts,
defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect
on the ability of such Investor to perform its obligations hereunder.


 


5.16.
No Rule 506 Disqualifying Activities. Such Investor has not taken any of the actions set forth in, and is not subject to, the
disqualification provisions of Rule 506(d)(1) of the 1933 Act.


 


5.17.
Residency. Such Investor is a resident of the jurisdiction specified below its address on the Schedule of Investors.


 


5.18.
ERISA. If Investor is (1) an employee benefit plan subject to Title I of ERISA, (2) a plan or account subject to Section 4975
of the Code or (3) an entity deemed to hold “plan assets” of any such plan or account, Investor hereby represents and warrants,
solely for purposes of assisting the Placement Agent in relying on the exception from fiduciary status under U.S. Department of Labor
Regulations set forth in Section 29 CFR 2510.3-21(c)(1), that a fiduciary acting on its behalf is causing the Investor to enter into
this Agreement and the transactions contemplated hereby and that such fiduciary:


 


(a)
is an entity specified in Section 29 CFR 2510.3-21(c)(1)(i)(A)-(E);


 


(b)
is independent (for purposes of Section 29 CFR 2510.3-21(c)(1)) of the Placement Agent;


 




    	19



     


    

 


(c)
is capable of evaluating investment risks independently, both in general and with regard to particular transactions and investment strategies,
including the Investor’s transaction hereunder;


 


(d)
has been advised that, with respect to the Placement Agent, neither the Placement Agent nor any of its affiliates has undertaken or will
undertake to provide impartial investment advice, or has given or will give advice in a fiduciary capacity, in connection with the Investor’s
transactions contemplated hereby;


 


(e)
is a “fiduciary” under Section 3(21)(a) of ERISA or Section 4975(e)(3) of the Code, or both, as applicable, with respect
to, and is responsible for exercising independent judgment in evaluating, the Investor’s transactions contemplated hereby; and


 


(f)
understands and acknowledges that no fees, compensation arrangements or financial interests provided for in connection with the transactions
contemplated hereby is a fee or other compensation for the provision of investment advice, and that neither the Placement Agent nor any
of its affiliates, nor any of their respective directors, officers, members, partners, employees, principals or agents, has received
or will receive a fee or other compensation from Investor or such fiduciary for the provision of investment advice in connection with
the Investor’s transactions contemplated hereby.


 


5.19.
Merger Agreement. Investor acknowledges that, as of the date hereof, (i) the Company is a party to the Merger Agreement, pursuant
to which the Company agreed to merge with Biosight as more specifically set forth in the Merger Agreement, (ii) the Merger (A) has not
closed, (B) may not close within the timeframe contemplated under the Merger Agreement and (C) in the event the Merger Agreement is terminated
in accordance with its own terms prior to any such closing, may not close at all (provided Closing hereunder is contingent upon closing
of the Merger), (iii) in connection with the Merger, the Company has filed a registration statement on Form S-4 that includes certain
information regarding Biosight, including the financial statements of Biosight (the “Biosight Information”), (iv)
the Biosight Information has not been and will not be provided to Investor prior to the Closing, and (v) Investor does not require the
Biosight Information to make its investment decision with respect to the purchase of the Shares and has otherwise had an opportunity
to receive, review and understand all information related to Biosight, the Merger Agreement and Merger requested by it and to ask questions
of and receive answers from the Company regarding Biosight, the Merger Agreement and the Merger, and has conducted and completed its
own independent due diligence.


 


6.
Conditions to Closing.


 


6.1.
Conditions to the Investors’ Obligations. The obligation of each Investor to purchase Shares at the Closing is subject to
the fulfillment to such Investor’s satisfaction, on or prior to the Closing Date, of the following conditions, any of which may
be waived by such Investor (as to itself only):


 


(a)
The representations and warranties made by the Company in Section 4 hereof shall be true and correct in all material respects (except
in the case of any representation or warranty qualified by materiality or Material Adverse Effect, which shall be true and correct in
all respects) as of the date hereof and on the Closing Date, except to the extent any such representation or warranty expressly speaks
as of an earlier date, in which case such representation or warranty shall be true and correct as of such earlier date. The Company shall
have performed in all material respects all obligations and covenants herein required to be performed by it on or prior to the Closing
Date.


 




    	20



     


    

 


(b)
The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for consummation of the
purchase and sale of the Shares and the consummation of the other transactions contemplated by the Transaction Documents, all of which
shall be in full force and effect.


 


(c)
The Company shall have executed and delivered the Registration Rights Agreement.


 


(d)
The Company shall have submitted to Nasdaq the notifications required for the listing of the Shares.


 


(e)
No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court
or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted
by any governmental authority, enjoining or preventing the consummation of the transactions contemplated hereby or in the other Transaction
Documents.


 


(f)
There shall have been no Material Adverse Effect with respect to the Company since the date hereof.


 


(g)
The Company shall have delivered a certificate, executed on behalf of the Company by its Chief Executive Officer or its Chief Financial
Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in subsections (a), (b), (d), (e), (f),
(i) and (k) of this Section 6.1.


 


(h)
The Company shall have delivered a Certificate, executed on behalf of the Company by its Secretary, dated as of the Closing Date, certifying
the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement and the other
Transaction Documents and the issuance of the Shares, certifying the current version of the certificate of incorporation and bylaws of
the Company and certifying as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf
of the Company.


 


(i)
The Investors shall have received an opinion from Morgan, Lewis & Bockius LLP, counsel for the Company, dated as of the Closing Date,
in form and substance reasonably acceptable to the Investors and addressing such legal matters as the Investors may reasonably request.


 


(j)
No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory body with respect
to public trading in the Common Stock.


 




    	21



     


    

 


(k)
Closing under the Merger Agreement shall have been consummated and the Merger shall have entered into effect.


 


6.2.
Conditions to Obligations of the Company. The Company’s obligation to sell and issue Shares at the Closing is subject to
the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which (other than
6.2(c)) may be waived by the Company:


 


(a)
The representations and warranties made by the Investors in Section 5 hereof shall be true and correct in all material respects (except
in the case of any representation or warranty qualified by materiality or Material Adverse Effect, which shall be true and correct in
all respects) when made, and shall be true and correct in all material respects on the Closing Date with the same force and effect as
if they had been made on and as of said date. The Investors shall have performed in all material respects all obligations and covenants
herein required to be performed by them on or prior to the Closing Date.


 


(b)
The Investors shall have executed and delivered the Registration Rights Agreement, the Investor Questionnaire.


 


(c)
Any Investor purchasing Shares at the Closing shall have paid in full its Subscription Amount to the Company at the same time that the
Company will issue the Shares to the Investor (PVD).


 


6.3.
Termination of Obligations to Effect Closing; Effects.


 


(a)
The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the Closing shall terminate as follows:


 


(i)
Upon the mutual written consent of the Company and Investors that agreed to purchase a majority of the Shares to be issued and sold pursuant
to this Agreement;


 


(ii)
By the Company if any of the conditions set forth in Section 6.2 shall have become incapable of fulfillment, and shall not have been
waived by the Company;


 


(iii)
By an Investor (with respect to itself only) if any of the conditions set forth in Section 6.1 shall have become incapable of fulfillment,
and shall not have been waived by the Investor (it being clarified, in the event the Merger Agreement is terminated or incapable of fulfillment
in accordance with its own terms, the condition under Section 6.1(k) shall be deemed incapable of fulfillment);


 


provided,
however, that, except in the case of clause (i) above, the party seeking to terminate its obligation to effect the Closing shall not
then be in breach of any of its representations, warranties, covenants or agreements contained in this Agreement or the other Transaction
Documents if such breach has resulted in the circumstances giving rise to such party’s seeking to terminate its obligation to effect
the Closing.


 




    	22



     


    

 


(b)
In the event of termination by the Company or any Investor of its obligations to effect the Closing pursuant to this Section 6.3, written
notice thereof shall be given to the other Investors by the Company and the other Investors shall have the right to terminate their obligations
to effect the Closing upon written notice to the Company and the other Investors. Nothing in this Section 6.3 shall be deemed to release
any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction Documents
or to impair the right of any party to compel specific performance by any other party of its obligations under this Agreement or the
other Transaction Documents.


 


7.
Covenants and Agreements of the Company.


 


7.1.
Information. From the date hereof until the Closing, the Company will make reasonably available to the Investors’ representatives,
consultants and their respective counsels for inspection, such information and documents as the Investor reasonably requests, and will
make available at reasonable times and to a reasonable extent officers and employees of the Company to discuss the business and affairs
of the Company; provided, however, that in no event shall the Company be required to disclose material nonpublic information to the Investors,
or to advisors to or representatives of the Investors.


 


7.2.
Insurance. The Company shall not materially reduce the insurance coverages described in Section 4.24.


 


7.3.
Nasdaq Listing. The Company will use commercially reasonable efforts to continue the listing and trading of the Common Stock (or,
following the Merger, the Merged Company Common Stock) on Nasdaq and, in accordance, therewith, will use commercially reasonable efforts
to comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of such exchange.


 


7.4.
Termination of Covenants. The provisions of Sections 7.1 and 7.3 shall terminate and be of no further force and effect on the
date on which the Company’s obligations under the Registration Rights Agreement to register or maintain the effectiveness of any
registration covering the Registrable Securities (as such term is defined in the Registration Rights Agreement) shall terminate.


 


7.5.
No Conflicting Agreements. The Company will not take any action, enter into any agreement or make any commitment that would conflict
or interfere in any material respect with the Company’s obligations to the Investors under the Transaction Documents.


 


7.6.
Form D. The Company agrees to timely file a Form D with respect to the Shares as required under Regulation D and to provide a
copy thereof, promptly upon request of an Investor.


 




    	23



     


    

 


7.7.
Removal of Legends.


 


(a)
In connection with any sale, assignment, transfer or other disposition of the Shares by an Investor pursuant to Rule 144 or pursuant
to any other exemption under the 1933 Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor
with the requirements of this Agreement, if requested by the Investor, the Company shall cause the transfer agent for the Common Stock
(the “Transfer Agent”) to timely remove any restrictive legends related to the book entry account holding such Shares
and make a new, unlegended entry for such book entry Shares sold or disposed of without restrictive legends within two Business Days
of the request of the Investor, provided that the Company has received from the Investor customary representations and other documentation
reasonably acceptable to the Company in connection therewith.


 


(b)
Subject to receipt from the Investor by the Company and the Transfer Agent of customary representations and other customary documentation
reasonably acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of (i) the Shares being subject
to an effective registration statement covering the resale of the Shares, (ii) such time as the Shares have been sold pursuant to Rule
144, or (iii) such time as the Shares are eligible for resale under Rule 144(b)(1) or any successor provision (such earliest date, the
“Effective Date”), the Company shall (A) deliver to the Transfer Agent irrevocable instructions that the Transfer
Agent shall make a new, unlegended entry for such book entry Shares, and (B) cause its counsel to deliver to the Transfer Agent, no later
than two Trading Days after the Effective Date, one or more opinions to the effect that the removal of such legends in such circumstances
may be effected under the 1933 Act if required by the Transfer Agent to effect the removal of the legend in accordance with such irrevocable
instructions and the other applicable provisions of this Agreement. The Company agrees that following the Effective Date or at such time
as such legend is no longer required under this Section 7.7, it will, no later than two Trading Days following the delivery by an Investor
to the Company or the Transfer Agent of a certificate representing Shares issued with a restrictive legend, deliver or cause to be delivered
to such Investor a certificate representing such shares that is free from all restrictive and other legends. The Company may not make
any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section
7.7. Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Investor by crediting the account of
the Investor’s prime broker with the DTC System as directed by such Investor. The Company shall be responsible for the fees of
its Transfer Agent and all DTC fees associated with such issuance.


 


(c)
Each Investor, severally and not jointly with the other Investors, agrees with the Company (i) that such Investor will sell any Shares
pursuant to either the registration requirements of the 1933 Act, including any applicable prospectus delivery requirements, or an exemption
therefrom, (ii) that if Shares are sold pursuant to a registration statement, they will be sold in compliance with the plan of distribution
set forth therein and (iii) that if, after the effective date of the Registration Statement covering the resale of the Shares, such Registration
Statement is not then effective and the Company has provided notice to such Investor to that effect, such Investor will sell shares only
in compliance with an exemption from the registration requirements of the 1933 Act. Each Investor acknowledges that the removal of the
restrictive legend from certificates representing Shares as set forth in this Section 7.7 is predicated upon the Company’s reliance
upon this understanding and that any counsel to the Company will be entitled to rely on this acknowledgment in connection with the opinion(s)
described in Section 7.7(b).


 




    	24



     


    

 


7.8.
[Intentionally omitted.]


 


7.9.
Subsequent Equity Sales. From the date hereof until ninety (90) days after the Closing Date, without the consent of the Required
Investors, the Company shall not issue shares of Common Stock or Common Stock Equivalents. Notwithstanding the foregoing, the provisions
of this Section 7.9 shall not apply to (i) the issuance of securities pursuant to the Merger Agreement, (ii) the issuance of the Shares
hereunder, (iii) the issuance of shares of Common Stock or Common Stock Equivalents upon the conversion or exercise of any securities
of the Company outstanding on the date hereof or outstanding pursuant to clause (iv) below, (iv) the issuance of any shares of Common
Stock or Common Stock Equivalents pursuant to any Company stock-based compensation plans in existence on the date hereof (including any
such plans assumed in connection with the Merger) or (v) the issuance of any Common Shares or Common Share Equivalents upon the conversion
or exercise of any securities of the Company issued pursuant to the Merger Agreement.


 


7.10.
Use of Proceeds. The Company shall use the net proceeds from the sale of the Shares hereunder for the purpose set forth on Schedule
7.10 attached hereto following the Closing. Except as set forth on Schedule 7.10, the Company shall use the net proceeds from
the sale of the Shares hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion
of the Company’s debt (other than payment of trade payables in the ordinary course of the Company’s business and prior practices),
(b) for the redemption of any shares of Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation
or (d) in violation of FCPA or OFAC regulations.


 


7.11.
Pledge of Securities. The Company acknowledges and agrees that its Shares may be pledged by an Investor in connection with a bona
fide margin agreement or other loan or financing arrangement that is secured by the Shares. The pledge of Shares shall not be deemed
to be a transfer, sale or assignment of the Shares hereunder, and no Investor effecting a pledge of Shares shall be required to provide
the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement or any other Transaction
Document; provided that an Investor and its pledgee shall be required to comply with the provisions of the Transaction Documents, including
Section 7.7 hereof, in order to effect a sale, transfer or assignment of Shares to such pledgee.


 


7.12.
Short Sales and Confidentiality After the Date Hereof. Each Investor covenants that neither it nor any Affiliates acting on its
behalf or pursuant to any understanding with it will execute any Short Sales during the period from the date hereof until the earlier
of such time as (i) after the transactions contemplated by this Agreement are first publicly announced or (ii) this Agreement is terminated
in full. Each Investor covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the
Company, such Investor will maintain the confidentiality of all disclosures made to it in connection with this transaction (including
the existence and terms of this transaction).


 




    	25



     


    

 


7.13.
Adjustments in Share Numbers and Prices. In the event of any stock split, subdivision, dividend or distribution payable in shares
of Common Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares
of Common Stock), combination or other similar recapitalization or event occurring after the date hereof and prior to the Closing, each
reference in any Transaction Document to a number of shares or a price per share shall be deemed to be amended to appropriately account
for such event.


 


8.
Survival and Indemnification.


 


8.1.
Survival. The representations, warranties, covenants, and agreements contained in this Agreement shall survive the Closing for
a period of three hundred sixty five (365) days after the date hereof and thereafter shall have no further force and effect; provided
that, subject to Section 7.4, the terms of Section 7.7 shall survive beyond such period until such time as no Investor holds any of the
Shares.


 


8.2.
Indemnification by the Company. The Company agrees to indemnify and hold harmless each of the Investors, the officers, directors,
partners, members, and employees of each Investor, each Person who controls any such Investor (within the meaning of Section 15 of the
1933 Act or Section 20 of the 1934 Act) and the officers, directors, partners, members and employees of each such controlling Person
(each, an “Investor Indemnified Party”), against any losses, claims, damages, liabilities or expenses, joint or several,
to which such Investor Indemnified Party may become subject under the 1933 Act, the 1934 Act, or any other federal or state statutory
law or regulation (including in settlement of any litigation, if such settlement is effected with the written consent of the Company),
insofar as such losses, claims, damages, liabilities or expenses (or actions in respect thereof as contemplated below) arise out of or
are based in whole or in part on the inaccuracy in the representations and warranties of the Company contained in this Agreement or the
failure of the Company to perform its obligations hereunder, and will reimburse each Investor Indemnified Party for legal and other expenses
reasonably incurred as such expenses are reasonably incurred by such Investor Indemnified Party in connection with investigating, defending,
settling, compromising or paying such loss, claim, damage, liability, expense or action; provided, however, that the Company will not
be liable in any such case to the extent that any such loss, claim, damage, liability or expense arises out of or is based upon (i) the
failure of such Investor Indemnified Party (or its related parties) to comply with the covenants and agreements contained herein, or
(ii) the inaccuracy of any representations made by such Investor Indemnified Party (or its related parties) herein.


 




    	26



     


    

 


8.3.
Indemnification Procedure. Promptly after any Investor Indemnified Party has received notice of any indemnifiable claim hereunder,
or the commencement of any action, suit or proceeding by a third Person, which the Investor Indemnified Party believes in good faith
is an indemnifiable claim under this Agreement, the Investor Indemnified Party shall give the Company written notice of such claim or
the commencement of such action, suit or proceeding, but failure to so notify the Company will not relieve the Company from any liability
it may have to such Investor Indemnified Party hereunder except to the extent that the Company is materially prejudiced by such failure.
Such notice shall state the nature and the basis of such claim to the extent then known. The Company shall have the right to defend and
settle, at its own expense and by its own counsel who shall be reasonably acceptable to the Investor Indemnified Party, any such matter
as long as the Company pursues the same diligently and in good faith. If the Company undertakes to defend or settle, it shall promptly
notify the Investor Indemnified Party of its intention to do so, and the Investor Indemnified Party shall cooperate with the Company
and its counsel in all commercially reasonable respects in the defense thereof and the settlement thereof. Such cooperation shall include,
but shall not be limited to, furnishing the Company with any books, records and other information reasonably requested by the Company
and in the Investor Indemnified Party’s possession or control. Such cooperation of the Investor Indemnified Party shall be at the
cost of the Company. After the Company has notified the Investor Indemnified Party of its intention to undertake to defend or settle
any such asserted liability, and for so long as the Company diligently pursues such defense, the Company shall not be liable for any
additional legal expenses incurred by the Investor Indemnified Party in connection with any defense or settlement of such asserted liability;
provided, however, that the Investor Indemnified Party shall be entitled (a) at its expense, to participate in the defense of such asserted
liability and the negotiations of the settlement thereof and (b) if (i) the Company has failed to assume the defense or employ counsel
reasonably acceptable to the Investor Indemnified Party or (ii) if the defendants in any such action include both the Investor Indemnified
Party and the Company and counsel to the Investor Indemnified Party shall have concluded that there may be reasonable defenses available
to the Investor Indemnified Party that are different from or in addition to those available to the Company or if the interests of the
Investor Indemnified Party reasonably may be deemed to conflict with the interests of the Company, then the Investor Indemnified Party
shall have the right to select a separate counsel and to assume such legal defense and otherwise to participate in the defense of such
action, with the expenses and fees of such separate counsel and other expenses related to such participation to be reimbursed by the
Company as incurred. Notwithstanding any other provision of this Agreement, the Company shall not settle any indemnified claim without
the consent of the Investor Indemnified Party, unless the settlement thereof imposes no liability or obligation on, and includes a complete
release from liability of, and does not include any admission of wrongdoing or malfeasance by, the Investor Indemnified Party.


 


9.
Miscellaneous.


 


9.1.
Successors and Assigns. This Agreement may not be assigned by a party hereto without the prior written consent of the Company
or the Investors, as applicable, provided, however, that an Investor may assign its rights and delegate its duties hereunder in whole
or in part to an Affiliate or to a third party acquiring some or all of its Shares in a transaction complying with applicable securities
laws without the prior written consent of the Company or the other Investors, provided such assignee agrees in writing to be bound by
the provisions hereof that apply to Investors. The provisions of this Agreement shall inure to the benefit of and be binding upon the
respective permitted successors and assigns of the parties. Without limiting the generality of the foregoing, in the event that the Company
is a party to a merger, consolidation, share exchange or similar business combination transaction in which the Common Stock are converted
into the equity securities of another Person, from and after the effective time of such transaction, such Person shall, by virtue of
such transaction, be deemed to have assumed the obligations of the Company hereunder, the term “Company” shall be deemed
to refer to such Person and the term “Shares” shall be deemed to refer to the securities received by the Investors in connection
with such transaction. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto
or their respective permitted successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement,
except as expressly provided in this Agreement.


 




    	27



     


    

 


9.2.
Counterparts; Faxes; E-mail. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. This Agreement may also be executed via facsimile or e-mail,
which shall be deemed an original.


 


9.3.
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement.


 


9.4.
Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall
be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed given upon such
delivery, (ii) if given by e-mail, then such notice shall be deemed given when directed to an electronic mail address at which the stockholder
has consented to receive notice, (iii) if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such
notice by the recipient or (B) three days after such notice is deposited in first class mail, postage prepaid, and (iv) if given by an
internationally recognized overnight air courier, then such notice shall be deemed given one Business Day after delivery to such carrier.
All notices shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate
by ten days’ advance written notice to the other party:


 


	 	If
    to the Company: 
	 	 	 
	 	 	Advaxis,
    Inc.
	 	 	9
    Deer Park Drive, Suite K-1
	 	 	Monmouth
    Junction, NJ 08852
	 	 	Attn:
    Kenneth A. Berlin, 
	 	 	President
    and Chief Executive Officer 
	 	 	E-mail:
    berlin@advaxis.com 
	 	 	 
	 	 	With
    a copy (which shall not constitute notice) to: 
	 	 	 
	 	 	Morgan,
    Lewis & Bockius LLP
	 	 	1701
    Market Street 
	 	 	Philadelphia,
    PA 19013 
	 	 	Attn:
    Justin W. Chairman, Esq.
	 	 	E-mail:
    justin.chairman@morganlewis.com
	 	 	 
	 	If
    to the Investors: 
	 	 	 
	 	 	to
    the addresses set forth on the signature pages hereto. 


 


9.5.
Expenses. The parties hereto shall pay their own costs and expenses in connection herewith regardless of whether the transactions
contemplated hereby are consummated; it being understood that each of the Company and each Investor has relied on the advice of its own
respective counsel. In the event that legal proceedings are commenced by any party to this Agreement against another party to this Agreement
in connection with this Agreement or the other Transaction Documents, the party or parties which do not prevail in such proceedings shall
severally, but not jointly, pay their pro rata share of the reasonable attorneys’ fees and other reasonable documented out-of-pocket
costs and expenses incurred by the prevailing party in such proceedings.


 




    	28



     


    

 


9.6.
Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company
and (a) prior to the Closing, Investors that agreed to purchase a majority of the Shares to be issued and sold pursuant to this Agreement
and (b) following the Closing, the Required Investors. Notwithstanding the foregoing, this Agreement may not be amended and the observance
of any term of this Agreement may not be waived with respect to (i) any Investor without the written consent of such Investor unless
such amendment or waiver applies to all Investors in the same fashion; (ii) the condition to Closing under Section 6.1(k) without the
consent of each Investor (provided each Investor may waive such condition solely for itself); or (iii) the Subscription amount of an
Investor without the consent of such Investor. Any amendment or waiver effected in accordance with this paragraph shall be binding upon
(i) prior to Closing, each Investor and (ii) following the Closing, each holder of any Shares purchased under this Agreement at the time
outstanding, and in each case, each future holder of all such Shares and the Company.


 


9.7.
Publicity. Except as set forth below, no public release or announcement concerning the transactions contemplated hereby shall
be issued by the Company or the Investors without the prior written consent of the Company (in the case of a release or announcement
by the Investors) or the Required Investors (in the case of a release or announcement by the Company) (which consents shall not be unreasonably
withheld or delayed), except as such release or announcement may be required by law or the applicable rules or regulations of any securities
exchange or securities market. By 9:00 A.M. (New York City time) on the Trading Day immediately following the date of this Agreement,
the Company shall issue a press release disclosing all material terms of transactions contemplated by this Agreement (the “Press
Release”). No later than 5:30 p.m. (New York City time) on the fourth Business Day following the date of this Agreement, the
Company will file a Current Report on Form 8-K (the “8-K”) attaching the press release described in the foregoing
sentence as well as copies of the Transaction Documents. The parties acknowledge that from and after the filing of the 8-K, no Investor
shall be in possession of any material, nonpublic information received from the Company or any of its respective officers, directors,
employees or agents, regarding the transactions contemplated by the Transaction Agreements.


 


9.8.
Third-Party Beneficiaries. Each of the Company and each Investor acknowledges and agrees that the Placement Agent is a third-party
beneficiary of the representations and warranties contained in Sections 4 and 5, respectively.


 


9.9.
Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be
interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition
or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the
extent permitted by applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable
in any respect.


 




    	29



     


    

 


9.10.
Entire Agreement. This Agreement, including the signature pages, Exhibits and the Disclosure Schedules, and the other Transaction
Documents constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede
all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter hereof and thereof.


 


9.11.
Further Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other actions
as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein
contained.


 


9.12.
Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance
with, the internal laws of the State of New York without regard to the choice of law principles thereof. Each of the parties hereto irrevocably
submits to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District
Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising out of
this Agreement and the transactions contemplated hereby (each, a “Related Proceeding”). Service of process in connection
with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified
for the giving of notices under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such court
in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to
the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit,
action or proceeding brought in any such court has been brought in an inconvenient forum. To the extent that the Company has or hereafter
may acquire any immunity (on the grounds of sovereignty or otherwise) from the jurisdiction of any court or from any legal process with
respect to itself or its property, the Company irrevocably waives, to the fullest extent permitted by law, such immunity in respect of
any such suit, action or proceeding. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH
RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.


 


9.13.
Independent Nature of Investors’ Obligations and Rights. The obligations of each Investor under any Transaction Document
are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance
of the obligations of any other Investor under any Transaction Document. The decision of each Investor to purchase Shares pursuant to
the Transaction Documents has been made by such Investor independently of any other Investor. Nothing contained herein or in any Transaction
Document, and no action taken by any Investor pursuant thereto, shall be deemed to constitute the Investors as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Investor acknowledges that no other
Investor has acted as agent for such Investor in connection with making its investment hereunder and that no Investor will be acting
as agent of such Investor in connection with monitoring its investment in the Shares or enforcing its rights under the Transaction Documents.
Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out
of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Investor to be joined as an
additional party in any proceeding for such purpose. The Company acknowledges that each of the Investors has been provided with the same
Transaction Documents for the purpose of closing a transaction with multiple Investors and not because it was required or requested to
do so by any Investor.


 


[remainder
of page intentionally left blank]


 




    	30



     


    

 


IN
WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the
date first above written.


 


	COMPANY:	ADVAXIS,
    INC.  
	 	 	 
	 	By:	       
	 	Name:
    	 
	 	Title:
    	 


 




    	 



     


    




 


	INVESTOR:	 	 
	 	By:	 
	 	Name:

    Title:
	 

     



 


	Investor
    Information	 
	Entity
                                            Name:

    

    
	 
	 	 
	Contact
                                            Person:

    

    
	 
	 	 
	Address:

    

    
	 
	 	 
	City:

    

    
	 
	 	 
	State:

    

    
	 
	 	 
	Zip
                                            Code:

    

    
	 
	 	 
	Telephone:

    

    
	 
		 
	Facsimile:

    

    
	 
	 	 
	Email:

    

    
	 
	 	 
	Tax
                                            ID # or Social Security #:

    

    
	 
	 	 
	Name
                                            in which Shares should be issued:

                                                         
	 



 






    	31



     


    




 


EXHIBIT
A


 


Schedule
of Investors


 


	Investor Name and Address	 	Number of Shares to be Purchased	 	 	Aggregate Purchase Price of Shares	 
		 	 	        	 	 	$	        	 
	 	 	 	 	 	 	$		 
	 	 	 	 	 	 	$		 



 




    	31



     


    

 


EXHIBIT
B


 


Form
of Registration Rights Agreement


 




    	32



     


    

 


EXHIBIT
C


 


Form
of Investor Questionnaire


 




    	 



     


    




 


ADVAXIS,
INC.


 


ACCREDITED
INVESTOR QUALIFICATION QUESTIONNAIRE


 


This
Questionnaire is being distributed to certain individuals and entities which may be offered the opportunity to purchase securities (the
“Securities”) of Advaxis, Inc., a Delaware corporation
(the “Company”). The purpose of this Questionnaire is to assure the Company that all such offers and purchases
will meet the standards imposed by the Securities Act of 1933, as amended (the “Act”), and applicable state
securities laws.


 


All
answers will be kept confidential. However, by signing this Questionnaire, the undersigned agrees that the Company and its counsel may
rely on the information set forth in this Questionnaire for purposes of complying with all applicable securities laws and may present
this Questionnaire to such parties as it reasonably deems appropriate if called upon to establish its compliance with such securities
laws.


 


If
the proposed investor is an individual, complete the Section below entitled “For Individual Investors.” If the proposed investor
is an entity, skip the Section below and instead complete the Section entitled “For Entity Investors.”


 


Please
complete, sign, date and return one copy of this Questionnaire to _________ of Morgan, Lewis & Bockius, LLP, the Company’s
legal counsel, via email (________). If the answer to a question is “none” or “not applicable,” please
so state.


 






    	 



     


    




 


For
                                            Entity Investors








 


In
the case of entities, this Questionnaire should be completed by the person who will be making the investment decision on behalf of the
entity (the “Decision-Maker”). All questions should be completed with respect to the entity (i.e., “you”
means the entity), unless otherwise directed.


 


1.
Residence Information. Please provide the entity’s full legal name, primary business address, phone number, fax number, name
and e-mail address of contact person, and federal tax I.D. number.


 


	 	 
	 	 
	 	 
	 	 


 


2.
Domicile Information. Please indicate the form of the entity and the state and date of its organization (e.g., corporation,
state and date of incorporation).


 


	 	Form	 
	 	State
    of Organization	 
	 	Date
    of Organization	 


 


3.
Accredited Investor Certification. The undersigned makes one of the following representations regarding its net worth and certain
related matters and has checked the applicable representation:


 


	☐	(i)	The
    undersigned is a trust with total assets in excess of $5,000,000 whose purchase is directed by a person with such knowledge and experience
    in financial and business matters that such person is capable of evaluating the merits and risks of the prospective investment.
	 	 	 
	☐	(ii)	The
    undersigned is a bank, insurance company, investment company registered under the United States Investment Company Act of 1940, as
    amended (the “Companies Act”), a broker or dealer registered pursuant to Section 15 of the United States
    Securities Exchange Act of 1934, as amended, a business development company, a Small Business Investment Company licensed by the
    United States Small Business Administration, a plan with total assets in excess of $5,000,000 established and maintained by a state
    for the benefit of its employees, or a private business development company as defined in Section 202(a)(22) of the United States
    Investment Advisers Act of 1940, as amended.
	 	 	 
	☐	(iii)	The
    undersigned is an employee benefit plan and either all investment decisions are made by a bank, savings and loan association,
    insurance company, or registered investment advisor, or the undersigned has total assets in excess of $5,000,000 or,
    if such plan is a self-directed plan, investment decisions are made solely by persons who are accredited investors.
	 	 	 
	☐	(iv)	The
    undersigned is a corporation, partnership, business trust, not formed for the purpose of acquiring the Securities, or an organization
    described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the “Code”), in each case
    with total assets in excess of $5,000,000.
	 	 	 
	☐	(v)	The
    undersigned is an entity in which all of the equity owners (in the case of a revocable living trust, its grantor(s)) qualify
    under any of the above subparagraphs, or, if an individual, each such individual has a net worth 1, either individually
    or upon a joint basis with such individual’s spouse, in excess of $1,000,000 (within the meaning of such terms as used in the
    definition of “accredited investor” contained in Rule 501 under the Securities Act), or has had
    an individual income 2 in excess of $200,000 for each of the two most recent years, or a joint income with such individual’s
    spouse in excess of $300,000 in each of those years, and has a reasonable expectation of reaching the same income level in the current
    year. 
	 	 	 
	☐	(vi)	The
    undersigned cannot make any of the representations set forth in paragraphs “i” through “v” above. 3


 


The
undersigned represents that the information contained herein is complete and accurate and may be relied upon by the Company, and that
the undersigned will notify the Company of any material change in any of such information prior to the undersigned’s investment
in the Company.


  


 









1
For purposes of this Questionnaire, “net worth” means the excess of total assets, excluding an individual’s
primary residence, at fair market value over total liabilities, including such individual’s mortgage or any other liability secured
by his or her primary residence only if and to the extent that it exceeds the value of the primary residence.


 


2
For purposes of this Questionnaire, “income” means adjusted gross income, as reported for federal income
tax purposes, increased by the following amounts: (a) the amount of any tax exempt interest income received, (b) the amount
of losses claimed as a limited partner in a limited partnership, (c) any deduction claimed for depletion, (d) amounts contributed
to an IRA or Keogh retirement plan, (e) alimony paid, and (f) any amounts by which income from long-term capital gains has
been reduced in arriving at adjusted gross income pursuant to the provisions of Section 1202 of the Internal Revenue Code.


 


3
See footnote 1.



 




    	 



     


    

  


In
Witness Whereof, the undersigned has executed this
Investor Qualification Questionnaire as of the date written below.


 


	 	_________________________________________________
	 	Name
    of Entity
	 	 
	 	By:______________________________________________
	 	 
	 	_________________________________________________
	 	Title
    or Association with Entity
	 	 
	 	_________________________________________________
	 	Date
    Signed


 




    	 



     


    

 


Schedule
7.10


 


Use
of Proceeds


 


To
fund multiple clinical trials as well as working capital and for general corporate purposes.